ClinicalTrials.gg
TerminatedNCT00356525Updated Aug 17, 2010Results posted

Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

A Phase 2 interventional study of pemetrexed and gemcitabine in Lung Neoplasms, sponsored by Eli Lilly and Company. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-08-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
Stopped early due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies testing pemetrexed in Lung Neoplasms — 6 open to participants now, 10 under way, 4 of them phase 3. Pemetrexed · Lung Neoplasms.

Enrollment
43rd of 69
41 · median 48
Started
2006
with 12 others
Phase 2
47 of 71
3 open now
Registered
23rd of 71
by date
Lead sponsor
8 of 71
Eli Lilly and Company

Among the 71 studies testing pemetrexed in Lung Neoplasms, this one is the 43rd largest by enrollment of the 69 interventional ones that give a count, is one of 13 that started in 2006, is one of 47 in phase 2, and was the 23rd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

6 of the 71 studies testing pemetrexed in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies testing pemetrexed in Lung Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to help answer:

  • Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last
  • Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer
03

Conditions studied

  • Lung Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You have non-small cell lung cancer that has come back () after initial treatment with surgery and chemotherapy.
  • You have good kidney, liver, and bone marrow organ function.
  • You are fully active or able to carry out light work such as housework or office work.

Exclusion criteria

Exclusion Criteria:

  • You have received pemetrexed or gemcitabine in the past for lung cancer
  • You are currently receiving another treatment for your lung cancer, or have had chemotherapy or certain other therapies for relapsed lung cancer in the past
  • You are unable to take drugs like dexamethasone
  • You are unable or unwilling to take the folic acid pills or Vitamin B12 injections that are required for the study
  • You are unable to stop taking aspirin or other drugs that control inflammation for certain periods of time during the study
  • You have had a heart attack in the last 6 months, or have other heart problems that are not controlled with medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Less Than One Year: Pemetrexed

    Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy

    Drug: pemetrexed · Drug: gemcitabine

  • Experimental
    Less Than One Year: Pemetrexed + Gemcitabine

    Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy

    Drug: Pemetrexed

  • Experimental
    One Year or Greater: Pemetrexed + Carboplatin

    Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy

    Drug: carboplatin · Drug: Pemetrexed

  • Experimental
    One Year or Greater: Pemetrexed + Gemcitabine

    Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy

    Drug: pemetrexed · Drug: gemcitabine

Interventions

  • 500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

    Also known as: LY231514, Alimta

  • 1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression

    Also known as: LY188011, Gemzar

  • area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression

  • 500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Objective Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to time of response (up to 17.5 months)

Secondary outcomes

  1. Overall Survival

    Overall survival is the number of participants who were alive when the trial was terminated.

    Time frame: baseline to trial termination (17.5 months)

  2. Time to Progressive Disease

    Time frame: baseline to measured progressive disease (up to 17.5 months)

  3. Duration of Response

    Time frame: time of response to progressive disease (up to 17.5 months)

  4. Time to Treatment Failure

    Time frame: baseline to stopping treatment (up to 17.5 months)

07

Results

Posted Jul 29, 2009
Limitations and caveats
The trial terminated early due to slow enrollment. Secondary outcomes were not analyzed due to insufficient data. Original results reported were interim analyses. Results have now been updated with final data.

Participant flow

Participant flow — Overall Study
MilestoneLess Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + Gemcitabine
Started141179
Completed0000
Not completed141179
Withdrew: Progressive disease8542
Withdrew: Adverse event1311
Withdrew: Lost to follow-up1000
Withdrew: Physician decision2221
Withdrew: Protocol entry criteria not met1000
Withdrew: Withdrawal by subject1103
Withdrew: Death0001
Withdrew: Sponsor decision0001

Outcome measures

PrimaryObjective Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to time of response (up to 17.5 months)
Reported as:
Number · participants
Objective Tumor Response
participantsLess Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + Gemcitabine
Complete Response0000
Partial Response7021
Stable Disease3956
Progressive Disease2201
Unknown2001
SecondaryOverall Survival

Overall survival is the number of participants who were alive when the trial was terminated.

Time frame:
baseline to trial termination (17.5 months)
Reported as:
Number · participants alive
Overall Survival
participants aliveLess Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + Gemcitabine
Overall Survival6 (1.64 to 16.10)4 (0.99 to 11.66)6 (4.40 to 17.58)7 (0.16 to 14.78)
SecondaryTime to Progressive Disease
Time frame:
baseline to measured progressive disease (up to 17.5 months)
Reported as:
Mean · months

No measurements were reported for this outcome.

SecondaryDuration of Response
Time frame:
time of response to progressive disease (up to 17.5 months)
Reported as:
Mean · months

No measurements were reported for this outcome.

SecondaryTime to Treatment Failure
Time frame:
baseline to stopping treatment (up to 17.5 months)
Reported as:
Mean · months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Less Than One Year: Pemetrexed—3/14 (21.4%)14/14 (100%)
Less Than One Year: Pemetrexed + Gemcitabine—5/11 (45.5%)11/11 (100%)
One Year or Greater: Pemetrexed + Carboplatin—0/7 (0%)7/7 (100%)
One Year or Greater: Pemetrexed + Gemcitabine—2/9 (22.2%)9/9 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventLess Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + Gemcitabine
Pericardial effusionCardiac disorders0/140/110/71/9
Lower gastrointestinal haemorrhageGastrointestinal disorders0/140/110/71/9
Rectal haemorrhageGastrointestinal disorders0/140/110/71/9
PneumoniaInfections and infestations0/141/110/71/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/140/110/71/9
Pleural effusionRespiratory, thoracic and mediastinal disorders1/140/110/71/9
Febrile neutropeniaBlood and lymphatic system disorders0/141/110/70/9
Atrial fibrillationCardiac disorders0/141/110/70/9
FatigueGeneral disorders0/141/110/70/9
Bronchopulmonary aspergillosisInfections and infestations0/141/110/70/9
Most frequent other events
Showing 10 of 210
Most frequent other events
EventLess Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + Gemcitabine
FatigueGeneral disorders11/1411/115/76/9
AnaemiaBlood and lymphatic system disorders6/1410/111/73/9
HypertensionVascular disorders5/146/115/75/9
NauseaGastrointestinal disorders9/146/113/76/9
CoughRespiratory, thoracic and mediastinal disorders5/144/114/72/9
DyspnoeaRespiratory, thoracic and mediastinal disorders8/146/114/73/9
ConstipationGastrointestinal disorders6/146/113/73/9
DepressionPsychiatric disorders2/146/111/72/9
Gastrooesophageal reflux diseaseGastrointestinal disorders7/141/110/71/9
PyrexiaGeneral disorders3/145/110/72/9

Baseline characteristics

Age, Customized
Age, Customized(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
<=65 years632415
>65 years885526
Sex: Female, Male
Sex: Female, Male(Participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
Female660416
Male857525
Region of Enrollment
Region of Enrollment(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
United States14117941
Disease Stage at Initial Diagnosis
Disease Stage at Initial Diagnosis(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
Stage IV14117941
Eastern Cooperative Oncology Group Performance Status
Eastern Cooperative Oncology Group Performance Status(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
0 - Fully Active632617
1 - Ambulatory, Restricted Strenuous Activity885324
History of Brain Metastates
History of Brain Metastates(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
No12117939
Yes20002
Prior Systemic Therapy
Prior Systemic Therapy(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
Adjuvant12116938
Neoadjuvant30115
Race/Ethnicity
Race/Ethnicity(participants)Less Than One Year: PemetrexedLess Than One Year: Pemetrexed + GemcitabineOne Year or Greater: Pemetrexed + CarboplatinOne Year or Greater: Pemetrexed + GemcitabineTotal
Black or African American00202
East Asian00011
West Asian00011
Caucasian14115737
08

Study locations

17 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33179, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evanston, Illinois 60201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55455, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Louis, Missouri 63110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chapel Hill, North Carolina 27599, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chattanooga, Tennessee 37404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Memphis, Tennessee 38120, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77060, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caxias Do Sul, 95070560, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90430-090, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santo Andre, 09090780, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560 029, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400016, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trivandrum, 695011, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2006
First posted
Jul 26, 2006
Start
Sep 2006
Primary completionActual
Jun 2008
CompletionActual
Apr 2009
Results first posted
Jul 29, 2009
Last update
Aug 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00356525
First posted
Jul 26, 2006
Start date
Sep 2006
Primary completion
Jun 2008
Completion
Apr 2009
Results posted
Jul 29, 2009
Last update
Aug 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Gemcitabine · Carboplatin

Start the discussion